RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

Latest Press Releases

RenovaCare to Present at BioNJ/JP Morgan/J&J BioPartnering Conference

Roseland, NJ – September 15, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will present at the tenth annual BioPartnering Conference, hosted by BioNJ and co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, scheduled for October 6 – 7, 2020.

Read more

RenovaCare Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility

Roseland, NJ – August 11, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its CellMist™ System from donor skin and applied topically with the SkinGun™ spray device for treatment of burn wounds.

Read more

Company Overview

RenovaCare, Inc. is committed to the highest standards of ethical behavior and the Company’s commitment extends to all aspects of its role as an employer and as a corporate citizen. This commitment to ethical behavior extends beyond mere compliance with laws and regulations to inspire our relationships with our shareholders, clients, and employees.

Corporate Office:

RenovaCare, Inc.
94 Hundred Corporate Center,
9375 E Shea Blvd, Suite 107-A
Scottsdale, AZ 85260
1-888-398-0202

Sign Up for Investor Alerts